Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with Nasdaq listing requirements.
The Company's common stock is expected to begin trading on a split-adjusted basis on August 18, 2025.
Stock Split Ratio
1 for 3 reverse stock split will reduce outstanding shares from 4.77 million to 1.59 million.
Listing Compliance
Reverse split is part of a plan to comply with Nasdaq Listing Rule 5550(a)(2).
CEO's Statement
Interim CEO, Richard Paolone, emphasized the importance of Nasdaq listing for shareholder value.
- The reverse stock split will consolidate shares, potentially increasing stock price per share.
- Enhanced visibility and credibility from Nasdaq listing can attract more investors and improve market perception.
Entero Therapeutics' strategic reverse stock split decision reflects its commitment to maintaining Nasdaq listing standards and enhancing shareholder value in a competitive market environment.